AW
ABUS icon

Avion Wealth’s Arbutus Biopharma ABUS Stock Holding History

Avion Wealth’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6K Hold
1,500
– – ﹤0.01% 600
2025
Q4 		$7K Hold
1,500
– – ﹤0.01% 566
2025
Q3 		$6K Hold
1,500
– – ﹤0.01% 589
2025
Q2 		$4K Hold
1,500
– – ﹤0.01% 648
2025
Q1 		$4K Hold
1,500
– – ﹤0.01% 565
2024
Q4 		$4K Hold
1,500
– – ﹤0.01% 563
2024
Q3 		$5K Buy
+1,500
New +$5.75K ﹤0.01% 505

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Avion Wealth's ABUS Position: Q1 2026 in Review

Avion Wealth held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 1,500 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #600.

Avion Wealth first reported a position in ABUS in Q3 2024 and has held it in 7 quarters since. The position peaked at $7K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Avion Wealth held 1,500 shares of Arbutus Biopharma worth $6K as of Q1 2026.
  • Avion Wealth left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Avion Wealth's portfolio in Q1 2026, its #600 holding.
  • Avion Wealth first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 7 quarters since.
  • Avion Wealth's Arbutus Biopharma position peaked at $7K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.